NEUROLOGY APIs · 8 MIN READ

Flupirtine Maleate API: sourcing a non-opioid analgesic

Published 16 May 2026 · Apex Pharma API technical team

Grade, salt form and the documentation to line up before you formulate.

Flupirtine Maleate is a non-opioid, centrally acting analgesic, and the first thing to settle when sourcing it is not the specification but the target market. Its regulatory status has varied by region over time, so confirming where you intend to sell is the step that should come before any conversation about grade or price.

What Flupirtine Maleate is used for

Flupirtine is a centrally acting analgesic used, where approved, for the management of pain without the opioid mechanism, which historically made it of interest for certain pain indications. It is supplied as an oral solid, typically in tablet or capsule form.

For a formulator, the appeal of a non-opioid analgesic is clear, but the indication and the availability are tied to the specific market’s regulatory position. That makes the market question the gate through which everything else passes.

Confirm the regulatory status for your target market first

Because the regulatory and market status of Flupirtine has changed in some jurisdictions, the single most important early check is whether the molecule is currently permitted, and under what conditions, in the market you are formulating for. This is a question for your regulatory affairs team, and it should be answered before you commit to a supplier.

Before you evaluate a Flupirtine Maleate specification, confirm the molecule is currently permitted in the market you intend to sell into — that check comes first.

A supplier can provide excellent material and complete documentation, and it will not help if the finished product cannot be registered in your target market. Settle the market question, then evaluate the material against the requirements that market imposes.

The salt form and grade selection

Flupirtine is supplied as the maleate salt, and the specification should state the salt form and confirm it through identity and assay, demonstrating both the Flupirtine base and the maleate counter-ion. Ask the supplier to make the salt form explicit rather than inferring it from the product name.

Confirm which monograph or in-house specification the material is controlled to, because compendial coverage is not uniform and you may be releasing against an in-house method. A price quoted against an in-house specification is not comparable to one quoted against a compendial grade, so ask which the number refers to.

Impurity profile, packaging and route consistency

Impurities follow the synthetic route, so ask whether the supplier’s route has changed recently and whether it will change during your contract — a route change hands you a new impurity profile to justify, which is a regulatory question before it is a quality one. Confirm the impurity limits on the specification and that the CoA reports results against them.

Confirm the pack sizes, liner configuration and storage conditions in writing, and specify the pack size at enquiry stage if your warehouse decants. Repacking after despatch adds a handling step your QA team has to document, and agreeing the configuration up front avoids it.

Documentation to request before the first PO

A batch Certificate of Analysis, the method of analysis, an MSDS and the product specification should be available before you order, with DMF or open-part documentation on request where your filing needs it. Confirm the salt form and impurity results are reported against stated limits on the CoA.

How quickly a supplier sends this set at enquiry stage is a reliable early signal of how they will perform later. Documentation turnaround before the PO tends to predict documentation turnaround when you have a shipment held at a port.